the aid library

SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch... more

Download (102)

View PDF (123)

COVID-19 rapid guideline: managing the long-term effects of COVID-19

NICE (2021) CC

This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations about care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of a... more

Download (81)

View PDF (151)

Joint Statement on Dose Donations of COVID-19 Vaccines to African Countries

African Union; Africa CDC Centres for Disease Control and Prevention (2021) CC

Download (114)

View PDF (149)

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022
recommended

World Health Organization WHO (2022) C_WHO

Contact tracing for COVID-19 is the process of identifying, assessing, and managing people who have been exposed to someone who has been infected with the SARS-CoV-2 virus, while quarantine is the separation of contacts from other people after exposure to a probable or confirmed case of SARS-CoV-2 i... more

Download (75)

View PDF (125)

COVID-19 in the Americas: Listening to the most vulnerable - Community perceptions from migrants, refugees, host communities and indigenous populations

The International Federation of Red Cross and Red Crescent Societies IFRC (2022) CC

This research report offers community perceptions of COVID-19 from migrants, refugees, host communities and indigenous populations in nine countries in the Americas: Argentina, Brazil, Bolivia, Colombia, Guatemala, Nicaragua, Jamaica, Panama and Trinidad and Tobago. It reveals the myriad impacts ... more

Download (40)

View PDF (520)

COVID-19 vaccine-specific resources

Open WHO; World Health Organization WHO (2022) C_WHO

Health workers involved in deployment and implementation of COVID-19 vaccination require vaccine-specific knowledge to ensure safe and efficient vaccine delivery. This training provides key information about COVID-19 vaccines through short instructional videos, vaccine explainers, job aids, topic br... more

Download (81)

View PDF (139)

Monthly Bulletin - COVID-19 vaccination in the African Region: Issue No. 03

World Health Organization WHO, Regional Office of Africa (2022) C_WHO

April 2022

Download (127)

View PDF (197)

WHO policy brief: Maintaining infection prevention and control measures for COVID-19 in health care facilities, 14 September 2022

World Health Organization WHO (2022) C_WHO

This document aims to encourage countries to develop and implement policies to maintain and strengthen IPC programmes and measures in health care facilities in the context of the current ongoing transmission of the SARS-CoV-2, with recognition that epidemiological trends may vary and the risk of tra... more

Download (54)

View PDF (101)

Covid-19 in Brazil in 2020: impact on deaths from cancer and cardiovascular diseases

Cordeiro Jardim, B.; et al. (2022) CC

Rev Saude Publica. 2022; 56: 22. Published online 2022 Apr 11. doi: 10.11606/s1518-8787.2022056004040

Download (114)

View PDF (186)

Note d’orientation : maintien des mesures de lutte anti-infectieuse contre la COVID-19 dans les établissements de santé, 14 septembre 2022

Organisation Mondiale de la Santé OMS (2022) C_WHO

Note d'orientation 7 juin 2022. Ce document a pour but d'encourager les pays à élaborer et à mettre en œuvre des politiques visant à maintenir et à renforcer les programmes et mesures de prévention des infections dans les établissements de soins de santé dans le contexte de la transmission... more

Download (51)

View PDF (106)

The sociodemographic impacts of the COVID-19 pandemic in Latin America and the Caribbean

United Nations ECLAC (2022) C1

Latin America and the Caribbean is characterized by a matrix of social inequality whose axes —such as socioeconomic stratum, gender, stage in the life cycle, ethnicity and race, territory, disability, and immigration status— create multiple, often concurrent, situations of exclusion and discri... more

Download (112)

View PDF (101)

Note d’orientation de l’OMS : Prise en charge clinique de la COVID-19

Organisation mondiale de la santé (OMS) (2022) C_WHO

Les notes d’orientation décrivent les mesures essentielles que les décideurs nationaux et infranationaux peuvent mettre en place concernant les aspects suivants de la lutte contre la COVID-19 : les tests de diagnostic, la prise en charge clinique, la réalisation des cibles en matière de vaccin... more

Download (87)

View PDF (109)

Note d’orientation de l’OMS : tests de diagnostic de la COVID-19

Organisation Mondiale de la Santé OMS (2022) C_WHO

Les notes d’orientation exposent les mesures essentielles que les décideurs peuvent mettre en œuvre aux niveaux national et infranational pour les éléments suivants : tests de diagnostic de la COVID-19, prise en charge clinique de la COVID-19, atteinte des cibles en matière de vaccination con... more

Download (117)

View PDF (166)

Reseña normativa de la OMS: mantenimiento de las medidas de prevención y control de la COVID-19 en los establecimientos de salud, 14 de septiembre de 2022

Organización Mundial de la Salud OMS (2022) C_WHO

Download (76)

View PDF (104)

Manejo clínico de la COVID-19, 14 de septiembre de 2022

Organisation Mondiale de la Santé OMS (2022) C_WHO

Reseña normativa de la OMS:

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Notes on the identification, diagnosis and treatment of patients with COVID-19 recommended

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022 recommended

Notes on the identification, diagnosis and treatment of patients with COVID-19
recommended

Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022
recommended